See more : WW International, Inc. (WW) Income Statement Analysis – Financial Results
Complete financial analysis of Dhunseri Ventures Limited (DPL.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dhunseri Ventures Limited, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- AK Medical Holdings Limited (1789.HK) Income Statement Analysis – Financial Results
- The Saudi National Bank (1180.SR) Income Statement Analysis – Financial Results
- CITIC Capital Acquisition Corp. (CCAC) Income Statement Analysis – Financial Results
- Otsuka Corporation (4768.T) Income Statement Analysis – Financial Results
- DBV Technologies S.A. (DBV.PA) Income Statement Analysis – Financial Results
Dhunseri Ventures Limited (DPL.BO)
About Dhunseri Ventures Limited
Dipna Pharmachem Ltd. engages in the trading and distribution of pharmaceutical raw material and chemical formulation products. Its raw material includes active pharmaceutical ingredients and excipient chemical formulation products. It also sells chemicals on commission basis. The company was founded on July 19, 2011 and is headquartered in Ahmedabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 3.51B | 2.07B | 2.39B | 1.23B | 465.59M |
| Cost of Revenue | 3.01B | 1.87B | 1.78B | 523.30M | 364.45M |
| Gross Profit | 504.63M | 199.03M | 610.02M | 704.15M | 101.13M |
| Gross Profit Ratio | 14.36% | 9.64% | 25.51% | 57.37% | 21.72% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 52.70M | 53.04M | 46.46M | 30.06M | 23.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 77.73M | 15.75M |
| SG&A | 52.70M | 53.04M | 46.46M | 30.06M | 23.59M |
| Other Expenses | 451.92M | 649.10M | 543.55M | 387.51M | 329.09M |
| Operating Expenses | 504.63M | 332.38M | 178.29M | -192.58M | 557.91M |
| Cost & Expenses | 3.51B | 2.20B | 1.96B | 330.72M | 922.36M |
| Interest Income | 255.52M | 109.24M | 85.45M | 120.20M | 173.86M |
| Interest Expense | 137.81M | 57.38M | 54.29M | 48.18M | 67.27M |
| Depreciation & Amortization | 287.05M | 220.30M | 227.25M | 255.17M | 275.21M |
| EBITDA | 2.36B | 7.46B | 4.78B | 3.09B | -368.21M |
| EBITDA Ratio | 67.03% | 361.25% | 199.98% | 252.01% | -79.09% |
| Operating Income | 0.00 | 7.24B | 4.55B | 2.84B | -643.42M |
| Operating Income Ratio | 0.00% | 350.58% | 190.47% | 231.23% | -138.20% |
| Total Other Income/Expenses | 1.93B | -61.95M | -52.02M | -52.20M | -253.92M |
| Income Before Tax | 1.93B | 7.18B | 4.50B | 2.79B | -710.69M |
| Income Before Tax Ratio | 54.94% | 347.58% | 188.30% | 226.97% | -152.65% |
| Income Tax Expense | 409.50M | 1.76B | 904.28M | 451.39M | -142.67M |
| Net Income | 1.53B | 5.42B | 3.59B | 2.32B | -547.27M |
| Net Income Ratio | 43.56% | 262.69% | 150.18% | 189.22% | -117.54% |
| EPS | 43.71 | 154.88 | 102.53 | 66.31 | -15.63 |
| EPS Diluted | 43.71 | 154.88 | 102.53 | 66.31 | -15.63 |
| Weighted Avg Shares Out | 35.02M | 35.02M | 35.02M | 35.02M | 35.02M |
| Weighted Avg Shares Out (Dil) | 35.02M | 35.02M | 35.02M | 35.02M | 35.02M |
Source: https://incomestatements.info
Category: Stock Reports